Taysha Gene Therapies (TSHA) Misses Q3 EPS by 76c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.93), $0.76 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $4.75 million versus the consensus estimate of $2.33 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• EquipmentShare raises 2026 outlook, approves $500M buyback
• Sempra names new CFO and SoCalGas CEO amid infrastructure deal